Next Article in Journal
Crossing the Border: Molecular Control of Motor Axon Exit
Next Article in Special Issue
Loop-Mediated Amplification Accelerated by Stem Primers
Previous Article in Journal
Caffeine Abolishes the Ultraviolet-Induced REV3 Translesion Replication Pathway in Mouse Cells
Previous Article in Special Issue
Applications of Next-Generation Sequencing Technologies to Diagnostic Virology
Int. J. Mol. Sci. 2011, 12(12), 8530-8538; doi:10.3390/ijms12128530

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer

1 ViennaLab Diagnostics GmbH, 1120 Vienna, Austria 2 Molecular Oncology Group, Department of Obstetrics and Gynecology, Medical University Vienna, 1090 Vienna, Austria 3 Ludwig Boltzmann Gesellschaft, Cluster Translational Oncology, 1090 Vienna, Austria 4 Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria 5 Department of Cardiothoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria
* Author to whom correspondence should be addressed.
Received: 18 September 2011 / Revised: 17 November 2011 / Accepted: 17 November 2011 / Published: 29 November 2011
(This article belongs to the Special Issue Advances in Molecular Diagnostics)
View Full-Text   |   Download PDF [239 KB, uploaded 19 June 2014]   |   Browse Figure


This study is aimed at evaluating the potential of a biochip assay to sensitively detect KRAS mutation in DNA from non-small cell lung cancer (NSCLC) tissue samples. The assay covers 10 mutations in codons 12 and 13 of the KRAS gene, and is based on mutant-enriched PCR followed by reverse-hybridization of biotinylated amplification products to an array of sequence-specific probes immobilized on the tip of a rectangular plastic stick (biochip). Biochip hybridization identified 17 (21%) samples to carry a KRAS mutation of which 16 (33%) were adenocarcinomas and 1 (3%) was a squamous cell carcinoma. All mutations were confirmed by DNA sequencing. Using 10 ng of starting DNA, the biochip assay demonstrated a detection limit of 1% mutant sequence in a background of wild-type DNA. Our results suggest that the biochip assay is a sensitive alternative to protocols currently in use for KRAS mutation testing on limited quantity samples.
Keywords: non-small cell lung cancer; KRAS; mutation detection; biochip hybridization non-small cell lung cancer; KRAS; mutation detection; biochip hybridization
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Kriegshäuser, G.; Fabjani, G.; Ziegler, B.; Zöchbauer-Müller, S.; End, A.; Zeillinger, R. Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2011, 12, 8530-8538.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert